Unknown

Dataset Information

0

An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.

ABSTRACT: Respiratory infections caused by human rhinovirus are responsible for severe exacerbations of underlying clinical conditions such as asthma in addition to their economic cost in terms of lost working days due to illness. While several antiviral compounds for treating rhinoviral infections have been discovered, none have succeeded, to date, in reaching approval for clinical use. We have developed a potent, orally available rhinovirus inhibitor 6 that has progressed through early clinical trials. The compound shows favorable pharmacokinetic and activity profiles and has a confirmed mechanism of action through crystallographic studies of a rhinovirus-compound complex. The compound has now progressed to phase IIb clinical studies of its effect on natural rhinovirus infection in humans.

SUBMITTER: Feil SC 

PROVIDER: S-EPMC4025830 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.

Feil Susanne C SC   Hamilton Stephanie S   Krippner Guy Y GY   Lin Bo B   Luttick Angela A   McConnell Darryl B DB   Nearn Roland R   Parker Michael W MW   Ryan Jane J   Stanislawski Pauline C PC   Tucker Simon P SP   Watson Keith G KG   Morton Craig J CJ  

ACS medicinal chemistry letters 20120213 4

Respiratory infections caused by human rhinovirus are responsible for severe exacerbations of underlying clinical conditions such as asthma in addition to their economic cost in terms of lost working days due to illness. While several antiviral compounds for treating rhinoviral infections have been discovered, none have succeeded, to date, in reaching approval for clinical use. We have developed a potent, orally available rhinovirus inhibitor 6 that has progressed through early clinical trials.  ...[more]

Similar Datasets

Unknown Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania.
| S-EPMC6219794 | biostudies-literature
Unknown EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.
| S-EPMC4434464 | biostudies-literature
Unknown Long-distance correlations of rhinovirus capsid dynamics contribute to uncoating and antiviral activity.
| S-EPMC3325699 | biostudies-literature
Unknown Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C.
| S-EPMC3957863 | biostudies-literature
Unknown Therapeutic and prophylactic activity of itraconazole against human rhinovirus infection in a murine model.
| S-EPMC4791555 | biostudies-literature
Unknown Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.
| S-EPMC34232 | biostudies-literature
Unknown Puquitinib, a novel orally available PI3K? inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
| S-EPMC5497803 | biostudies-literature
Unknown Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms.
| S-EPMC6535533 | biostudies-literature
Unknown Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance.
| S-EPMC3878079 | biostudies-literature
Unknown Dissociation of an antiviral compound from the internal pocket of human rhinovirus 14 capsid.
| S-EPMC1140408 | biostudies-literature